ASArun SanyalMD, MBBSVideoViral Hepatitis and Liver DiseaseHEP DART 2017NASH Globally: Pathways to Combination Therapy, Biomarkers and Outcomes | Arun SanyalView Video
VideoViral Hepatitis and Liver DiseaseHEP DART 2017Looking back to move forward: designing next-gen RNAi for best results in HBV | Bruce GivenView Video
VideoViral Hepatitis and Liver DiseaseHEP DART 2017HEV Update: Diagnostics and Management | Kenneth Sherman, MD, PhDView Video
FZFabien ZoulimMD, PhDVideoViral Hepatitis and Liver DiseaseHEP DART 2017Revisiting the Molecular and Cell Biology of the Hepatitis B Virus Towards Elimination | Fabien Zoulim, MD, PhDView Video
VideoViral Hepatitis and Liver DiseaseHEP DART 2017Update on Merck’s HCV Program | Mike RobertsonView Video
TATarik AsselahMD, PhDVideoViral Hepatitis and Liver DiseaseHEP DART 2017Pan-genotypic direct-acting antiviral agents: Opportunity to achieve HCV elimination | Tarik AsselahView Video
JFJordan FeldMD, MPHVideoViral Hepatitis and Liver DiseaseHEP DART 2017DAA Controversies: Do they Cause HBV Reactivation and/or HCC? | Jordan Feld, MD, MPHView Video
VideoViral Hepatitis and Liver DiseaseHEP DART 2017Management of HCV in Decompensated liver disease | Michael MannsView Video
MSMark SulkowskiMDVideoViral Hepatitis and Liver DiseaseHEP DART 2017Clinical Challenges in HCV infection | Mark Sulkowski, MDView Video
SLStephen LocarniniBSc(Hons), PhD, MBBS, FRC(Path)VideoViral Hepatitis and Liver DiseaseHEP DART 2017SB 9200: A novel RIG-I agonist for chronic hepatitis B | Stephen Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)View Video
VideoViral Hepatitis and Liver DiseaseHEP DART 2017Development of Immune Competent Small Animal Models for HBV | Helene Strick-MarchandView Video
VideoViral Hepatitis and Liver DiseaseHEP DART 2017Core Antibody: anti-HBc What is the Core of the Story? | Robert Gish, MDView Video
